{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:39:09Z","timestamp":1762529949987,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,8,10]],"date-time":"2016-08-10T00:00:00Z","timestamp":1470787200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["advancesradonc.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Radiation Oncology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.adro.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T22:19:08Z","timestamp":1472595548000},"page":"317-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study"],"prefix":"10.1016","volume":"1","author":[{"given":"Steven","family":"Gresswell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney E.","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Day","family":"Werts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell","family":"Fuhrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.adro.2016.08.005_bib1","first-page":"1","article-title":"National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, MD, June 15-17, 1987","year":"1988","journal-title":"NCI Monogr"},{"key":"10.1016\/j.adro.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2005.05.2530","article-title":"Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy","volume":"24","author":"Peeters","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0360-3016(02)02829-8","article-title":"Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial","volume":"53","author":"Pollack","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.adro.2016.08.005_bib6","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.brachy.2010.09.004","article-title":"Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function","volume":"10","author":"Valakh","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/S0360-3016(03)01319-1","article-title":"Brachytherapy versus brachytherapy plus external beam radiation for prostate cancer: A comparison of urinary symptoms and quality of life","volume":"57","author":"Jain","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib8","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1002\/cncr.26203","article-title":"Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809","volume":"117","author":"Hurwitz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2016.08.005_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/cncr.20446","article-title":"Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy","volume":"101","author":"Sarosdy","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-5347(05)65970-8","article-title":"Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated","volume":"166","author":"Talcott","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.adro.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0360-3016(01)02811-5","article-title":"Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy","volume":"53","author":"Kang","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib12","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/cncr.11595","article-title":"Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy","volume":"98","author":"Albert","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2016.08.005_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0360-3016(99)00176-5","article-title":"Urinary morbidity following ultrasound-guided transperineal prostate seed implantation","volume":"45","author":"Gelblum","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0360-3016(00)00632-5","article-title":"Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer","volume":"48","author":"Gelblum","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib15","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1016\/j.ijrobp.2011.11.040","article-title":"Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate","volume":"82","author":"Lawton","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bju.12514","article-title":"Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer","volume":"114","author":"Spratt","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2016.08.005_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","article-title":"Prostate cancer, version 1.2016","volume":"14","author":"Mohler","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.adro.2016.08.005_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S0360-3016(02)04527-3","article-title":"The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials","volume":"55","author":"Ghaly","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/pros.20118","article-title":"Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis","volume":"62","author":"Singh","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.adro.2016.08.005_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2007.12.002","article-title":"Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy","volume":"7","author":"Zelefsky","year":"2008","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2016.08.005_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijrobp.2012.03.004","article-title":"Meta-analysis of the alpha\/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?","volume":"85","author":"Vogelius","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib23","first-page":"1009","article-title":"Is the alpha\/beta ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?","volume":"33","author":"Fowler","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.adro.2016.08.005_bib24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ijrobp.2005.07.970","article-title":"Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial","volume":"64","author":"Pollack","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.semradonc.2008.04.007","article-title":"Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer","volume":"18","author":"Ritter","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib26","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12094-009-0382-2","article-title":"Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials","volume":"11","author":"Macias","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1748-717X-2-29","article-title":"Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I\/II feasibility study","volume":"2","author":"Junius","year":"2007","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib28","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ijrobp.2005.05.054","article-title":"Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes","volume":"63","author":"Kupelian","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib29","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ijrobp.2012.02.049","article-title":"Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer","volume":"84","author":"Arcangeli","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib30","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijrobp.2015.10.049","article-title":"NRG Oncology RTOG 0415: A randomized phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer","volume":"94","author":"Lee","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib32","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ijrobp.2009.09.078","article-title":"Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee","volume":"76","author":"Buyyounouski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/030089161109700109","article-title":"Image-guided stereotactic body radiation therapy for localized prostate cancer","volume":"97","author":"Kang","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.adro.2016.08.005_bib35","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ijrobp.2006.10.050","article-title":"Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results","volume":"67","author":"Madsen","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1748-717X-8-58","article-title":"Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience","volume":"8","author":"Chen","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1748-717X-8-118","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years","volume":"8","author":"Katz","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2013.08.030","article-title":"Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials","volume":"109","author":"King","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/1754-9485.12213","article-title":"Stereotactic body radiotherapy for primary prostate cancer: A systematic review","volume":"58","author":"Tan","year":"2014","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib40","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2005.07.981","article-title":"Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results","volume":"64","author":"Stock","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib42","doi-asserted-by":"crossref","DOI":"10.1118\/1.3181483","article-title":"Comparison of biological effective dose between protons and seed implant plus IMRT for prostate treatment","author":"Sheu","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.adro.2016.08.005_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2005.06.009","article-title":"The alpha\/beta ratio for prostate cancer: What is it, really?","volume":"76","author":"Bentzen","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.adro.2016.08.005_bib44","first-page":"521","article-title":"Alpha\/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications","volume":"169","author":"Deore","year":"1993","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.adro.2016.08.005_bib45","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1111\/bju.12166","article-title":"The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes","volume":"112","author":"Stock","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.adro.2016.08.005_bib46","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.brachy.2011.07.006","article-title":"Phase I\/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate","volume":"11","author":"Myers","year":"2012","journal-title":"Brachytherapy"},{"key":"10.1016\/j.adro.2016.08.005_bib47","doi-asserted-by":"crossref","first-page":"196","DOI":"10.5489\/cuaj.12121","article-title":"The best method for dose escalation: Prostate brachytherapy","volume":"6","author":"Morton","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.adro.2016.08.005_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cncr.22341","article-title":"Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death","volume":"109","author":"Alcantara","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.adro.2016.08.005_bib49","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.urology.2006.08.1056","article-title":"Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure","volume":"68","author":"Ray","year":"2006","journal-title":"Urology"}],"container-title":["Advances in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109416300501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452109416300501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T15:35:12Z","timestamp":1762529712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452109416300501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S2452109416300501"],"URL":"https:\/\/doi.org\/10.1016\/j.adro.2016.08.005","relation":{},"ISSN":["2452-1094"],"issn-type":[{"type":"print","value":"2452-1094"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study","name":"articletitle","label":"Article Title"},{"value":"Advances in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adro.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}